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Cellular retinoic acid binding proteins are considered 
to be involved in retinoic acid (RA) signaling pathways. 
Our aim was to compare the expression and localization 
of cellular retinoic acid binding proteins I and II (CRABP 
I and II) in embryonic mouse hearts during normal de-
velopment and after a single teratogenic dose of RA. 
Techniques such as real-time PCR, RT-PCR, Western blots 
and immunostaining were employed to examine hearts 
from embryos at 9–17 dpc. RA treatment at 8.5dpc af-
fects production of CRABP I and II in the heart in the 
48-h period. Changes in expression of mRNA for retinal-
dehyde dehydrogenase II (Raldh2), Crabp1 and Crabp2 
genes also occur within the same time window (i.e. 
10–11dpc) after RA treatment. In the embryonic control 
heart these proteins are localized in groups of cells with-
in the outflow tract (OT), and the atrioventricular endo-
cardial cushions. A gradient of labeling is observed with 
CRABP II but not for CRABP I along the myocardium of 
the looped heart at 11 dpc; this gradient is abolished in 
hearts treated with RA, whereas an increase of RALDH2 
staining has been observed at 10 dpc in RA-treated 
hearts. Some populations of endocardial endothelial 
cells were intensively stained with anti-CRABP II whereas 
CRABP I was negative in these structures. These results 
suggest that CRABP I and II are independently regulat-
ed during heart development, playing different roles in 
RA signaling, essential for early remodeling of the heart 
tube and alignment of the great arteries to their respec-
tive ventricles. 
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INTRODuCTION
Cellular retinoic acid binding proteins (CRABPs) are 
proteins of approximately 16–17 kDa, which bind retin-
oic acid (RA) with high affinity (Ong et al., 1994). They 
belong to the multigene family of intracellular lipid-bind-
ing proteins (ILBP) (see Bernlohr et al., 1997 for a re-
view). To this day two types of these proteins have been 
characterized: CRABP I (Ong et al., 1994) and CRABP 
II (Giguére et al., 1990). Both proteins are present in the 
embryo as well as in the adult, and their expression is 
time- and tissue-specific (Dekker et al., 1994; Bucco et al., 
1996), therefore each of these proteins is likely to have 
an important physiological function.
Both CRABP I and II are present in the cytoplasmic 
compartment of various cells (Gaub et al., 1998) and 
CRABP II is also found in the nucleus (Delva et al., 
1999). Due to this fact as well as their high affinity and 
specificity for RA (Dong et al., 1999) CRABPs are be-
lieved to messenger RA signaling in the cell. Both pro-
teins might contribute significantly to RA metabolism, 
but their biological role has not been fully elucidated. 
The levels of CRABPs in the embryo undergo dramatic 
changes during development. Expression of CRABP II 
in murine embryo seems to be more widespread and at a 
lower level than that of CRABP I (Leonard et al., 1995), 
and each of these is expressed in a tissue- and organ-
specific manner (Dekker et al., 1994; Bucco et al., 1996) 
suggesting different functions.
It has been demonstrated that upon binding retinoic 
acid CRABP I participates in RA catabolism by produc-
ing its inactive metabolites (Boylan & Gudas, 1992). Be-
cause of this CRABP I is thought to buffer the amount 
of free intercellular RA and alter its amount entering the 
nucleus (Maden et al., 1988; Perez-Castro et al., 1989). In 
this way CRABP I may prevent teratogenic effects of ex-
cessive RA levels on various tissues (Dingle et al., 1972) 
or may accumulate RA in the cells protecting them from 
possible hypovitaminosis A (Lampron et al., 1995). On 
the other hand, CRABP II might be involved in trans-
porting RA to the nucleus and therefore take part in the 
activation of nuclear RA receptors and regulation of RA-
dependent genes (McCaffery & Dräger, 2000; Ross et al., 
2000; Zhelyaznik et al., 2003; Theodosiou et al., 2010).
Furthermore, promoters of both CRABP genes con-
tain RA-response elements (RARE), being themselves 
targets for action of retinoic acid (Aström et al., 1991; 
Durand et al., 1992; Kleinjan et al., 1998). However, 
their regulation by RA seems to be tissue-specific (As-
tröm et al., 1991; Leonard et al., 1995). For instance an 
exogenous teratogenic dose of RA causes an increase of 
mRNA level for CRABP II in various cell lines and tis-
sues in vitro (Lyn & Giguére, 1994; Williams et al., 2004), 
whereas mRNA for CRABP I remains unaffected (Lyn 
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& Giguére, 1994). This may indicate that the two genes 
are regulated differently.
CRABPs are markers for neural crest cells (NCCs), 
their derivatives (Ruberte et al., 1990; Maden et al., 1991; 
Ilagan et al., 2006), and areas of intense morphogenetic 
processes in various embryonic tissues (Perez-Castro et 
al., 1989; Maden et al., 1991; Ruberte et al., 1992) that 
correspond to sites of endogenous RA synthesis (Berg-
gren et al., 1999; 2001; Zhelyaznik et al., 2003). CRABPs 
are also localized in areas prone to RA-related teratogen-
esis (Kalter & Warkany, 1961; Perez-Castro et al., 1989; 
Ruberte et al., 1990; Maden et al., 1990; Leonard et al., 
1995). 
It has been known for a long time, that RA, the ac-
tive metabolite of vitamin A, is a potent, ubiquitous 
morphogene, crucial for prenatal vertebrate development 
and that it may also act as a teratogenic agent under 
conditions of its deficiency (Wilson et al., 1953) or excess 
(Lammer et al., 1985; Bouman et al., 1995; Yasui et al., 
1995; 1997; 1999; Nakajima et al., 1996; 1997; Lee et al., 
1998). Among tissues prone to RA-related teratogenesis 
is the developing heart (Wilson et al., 1953; Lammer et 
al., 1985; Rosa et al., 1986; Bouman et al., 1995; Yasui 
et al., 1995; 1997; 1999; Nakajima et al., 1996; 1997; Lee 
et al., 1998; Sinning, 1998). The subpopulation of cells 
belonging to the second heart field (SHF) is important 
for heart tube development. The second heart field re-
quires precise levels of RA signaling in a narrow time-
window between 7.75 dpc and 10.5 dpc (Lavine et al., 
2005; Sirbu et al., 2008). SHF and its proper addition to 
the developing heart tube are essential for correct align-
ment of the great arteries and normal development of 
the outflow tract (OT) (Yelbuz et al., 2002; Waldo et al., 
2005). Both insufficiency and excess of local RA lead to 
serious cardiac defects, mostly within the OT region, for 
instance double outlet right ventricle (DORV), transposi-
tion of the great arteries (TGA), persistent truncus arte-
riosus (PTA), tetralogy of Fallot and others. RA signal-
ing to SHF cells is mediated by fibroblast growth factor 
8 (FGF8), whose proper amount is tightly controlled in 
SHF cells by RA (Ryckebush et al., 2008) and also by the 
cardiac neural crest cells (CNCCs) approaching the heart 
(Hutson et al., 2006). It has been demonstrated that the 
onset of RA-related teratogenesis within the heart oc-
curs at around 8 to 10 dpc (Wilson et al., 1953), which is 
when the NCCs are approaching and invading the heart 
(Hildreth et al., 2008). At that time (8 dpc) the cells of 
SHF are also added to the developing heart tube (Kelly 
et al., 2001).
We hypothesized that the expression and location of 
CRABP I and II in the developing heart may reflect 
the timeframe and areas of RA activity. Therefore, in 
this study we aimed to examine the expression and lo-
cation of CRABP I and II proteins in the mouse em-
bryonic heart during developmental stages from 9 dpc 
to 17 dpc and to compare these attributes with the de-
veloping hearts derived from RA-treated embryos. We 
propose that a single dose of RA administered at the 
time when the SHF cells contribute to the developing 
heart tube (Kelly et al., 2001) may alter the expression of 
CRABPs genes and location of CRABPs proteins. Addi-
tionally, one of our goals was to compare the expression 
of mRNAs for both proteins during normal heart devel-
opment and at corresponding stages after RA treatment. 
To study the possible relationship between CRABP I, 
II and endogenous RA we analyzed the location of reti-
naldehyde dehydrogenase II (RALDH2) — the key RA-
synthetic enzyme in hearts from control and RA-treated 
embryonic mice at the time of the assumed RA-mediated 
effect on the developing mouse heart (10–12 dpc).
MATeRIALS AND MeTHODS
The study was performed according to the require-
ments of the 2nd Local Ethical Committee at the Medi-
cal University of Warsaw.
The study was performed on Balb/c mouse inbred 
strain and on F1 cross of B57BL/6 and CBA mouse in-
bred strains. Balb/c and F1 cross females were mated 
with males of their respective strain for two hours in the 
morning. Spontaneous ovulation and subsequent mating 
was indicated by the presence of vaginal plugs. Mice that 
had succesfully mated were housed separately for the 
purpose of collecting embryos. The time of joining the 
males with the females was recorded and was counted 
as day “0” for all obtained pregnancies. The remaining 
females were mated on the following days until impreg-
nation.
At 8.5 dpc half of the pregnant females were treated 
i.p. with all-trans-retinoic acid (Sigma-Aldrich, St. Louis, 
MO, USA) dissolved in 100 μl of dimethylsulfoxide (Sig-
ma-Aldrich), at a dose of 70 mg/kg body weight Em-
bryos obtained from females that were not treated in any 
way (control embryos) served as comparison versus those 
exposed to a teratogenic dose of RA. In a pilot study 
performed on DMSO-treated control mice we obtained 
the same results with the RT-PCR method for CRABP 
I and II as on control non-treated mice. Three or more 
hearts or embryos were collected from every day of de-
velopment for each procedure. 
Hearts from control and RA-treated embryos were 
collected: 1. for RT-PCR and real-time PCR in RNase-
free conditions, immediately frozen and kept at –80 °C 
for further analysis; 2. for tissue paraffin sections fixed 
in 4 % buffered formaldehyde, rinsed with distilled water, 
dehydrated in increasing concentrations of ethanol and 
processed for paraffin embedding; 3. for Western blot in 
aseptic conditions, and immediately frozen and kept at 
–20 °C for further investigation. For Western blots with 
anti-CRABP I and II antibodies brains from embryos of 
all stages were also collected and kept frozen for further 
analysis. For Western blot with anti-RALDH2 antibodies 
the eye and the testis of adult mouse were collected as 
positive control tissue and kept frozen until used. 
Reverse transcription-polymerase chain reaction 
and real-time PCR. Total cellular RNA was extract-
ed by Qiazol extraction using a Tissue Lyser (Qiagen 
GmbH, Hilden, Germany), according to the instructions 
provided by the producer. Synthesis of cDNA was per-
formed on 0.5–1 µg of total RNA with oligo-dT prim-
ers for 1 h at 42 °C using RevertAid M-MuLV reverse 
transcriptase (Fermentas, Ontario, Canada) according to 
vendor΄s instruction.
PCR amplification with Taq polymerase was per-
formed using the following protocol: 1 cycle 94 °C for 2 
min, followed by 35 cycles of 94 °C for 45 s, 58 °C for 
45 s, 72 °C for 1 min.
Real-time PCR was carried out using a StepOnePlus 
apparatus (Applied Biosystem, Foster City, CA, USA) in 
a mixture containing 7.5 µl SYBR Green PCR Master 
Mix (SYBR Green qPCR Kit, Sigma, Poznań, Poland), 
specific primers and 50 ng of cDNA in a total volume 
of 15 µl using the following cycling conditions: 1 cycle 
of 95 °C for 15 min, followed by 40 cycles of 95 °C for 
45 s, 58 °C for 45 s, and 1 cycle of 72 °C for 45 s. Prim-
ers specific for Crabp I gene (5΄-TTC GCC GGT ACC 
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TGG AAG ATG-3΄, 5΄-CCC CCT CAA GAA GTG 
TCT GTG-3΄, for Crabp II gene (5΄-CGT GGA TGG 
GAG ACC CTG TAA G-3΄ and 5΄-CAG GCA GTT 
CTT GGA CCC GTA G-3΄), and for Raldh2 gene (5΄-
TCC ATT CAC CAC TCT TGC CTC A-3΄ and 5΄-
AGA AGG GAA GGA AGC CAG TGC T-3΄) were 
used. EF2 (elongation factor 2; 5′-GCG GTC AGC 
ACA ATG GCA TA-3′ and 5′-GAC ATC ACC AAG 
GGT GTG CAG-3′) was also amplified under the same 
conditions and was used as a housekeeping gene. PCR 
efficiency was determined for all three pairs of prim-
ers. All reactions were performed in duplicates. Controls 
containing SYBR Green PCR Master Mix and primers 
without sample cDNA emitted no fluorescence after 40 
cycles. Relative quantification of gene expression was 
calculated based on the comparative CT (threshold cycle 
value) method (ΔCT = CT gene of interest – CT house-
keeping gene). Comparison of gene expression in dif-
ferent samples was performed based on the differences 
in ΔCT of individual samples (ΔΔCT). Results obtained 
from four different experiments were used to determine 
the level of mRNA for examined proteins. All data are 
presented as means ± standard error (S.E.M.) and ana-
lyzed with Student΄s t-test. Differences were accepted as 
statistically significant at p < 0.05.
Western blot. Embryonic hearts and embryonic 
brains, collected at different days of development, as well 
as adult eye and testis were homogenized in extraction 
buffer (Ripa; 10 mM Tris/HCl; 0.15 M NaCl, 1 % Triton 
X-100; 1 % sodium deoxycholate; 0.1 % SDS), containing 
protease inhibitors (0.005 % aprotinin and 0.01 % phenyl-
methylsulfonyl fluoride (PMSF) at +4 °C. 
Protein determination. One µl of embryonic heart 
extract or extraction buffer (blank test) and 9 µl of de-
ionized water was placed in a flat-bottomed 96-well plate 
and 0.2 ml of BCA protein assay reagent (Pierce, Rock-
ford, Illinois, 61105 USA) was added to each well. The 
plate was incubated at 37 °C for 30 min. Protein con-
centration was determined spectrophotometrically at 550 
nm (SLT Spectra Labinstruments, Crailsheim, Germany). 
For RALDH2 blots total protein in lysates was deter-
mined with BCA™ Protein Assay (Thermo Scientific, 
Rockford, IL, USA). Protein transfer efficiency was de-
termined by staining membranes with 1 % Ponceau S in 
1 % acetic acid. After staining membranes were washed 
with 5 % acetic acid, photographed, destained with tap 
water and blocked with 5 % non-fat milk. Densitomet-
ric analysis was made with GelWorks 1 D Intermediate 
(UVP, Upland, CA, USA).
Electrophoresis and Western blotting. Embryonic 
heart extracts (10 µg of protein) mixed in sample buf-
fer with β-mercaptoethanol were separated by SDS/
polyacrylamide gel electrophoresis (SDS/PAGE; 12 % 
acrylamide) according to Laemmli (1970). Separated pro-
teins were transferred onto PVDF membrane (Invitro-
gen, Carlsbad, CA, USA) by semi-dry blotting at 25 V 
for 30 min, using a Trans-Blot SD apparatus (Bio-Rad 
Laboratories, Hercules, CA, USA). The membrane was 
incubated overnight with blocking buffer PBS (phos-
phate-buffered saline), pH 7.4, containing 0.1 % Tween 
and 2 % non-fat milk. Then the membrane was incu-
bated overnight with primary antibody. For CRABP I 
the primary antibody was obtained from Chemicon (Bil-
lerica, MA, USA; cat. No. MAB5484) or from Abcam 
(Cambridge, UK, cat. No. ab2816), whereas for CRABP 
II an antibody from Chemicon (cat. No. MAB5486) was 
used. Anti-RALDH2 antibody was a gift from Peter Mc-
Caffery and was used for immunohistochemical staining. 
For Western blot anti-RALDH2 antibody was also ob-
tained from Santa Cruz Biotechnology Inc. (Santa Cruz, 
CA, USA, ALDH1A2, cat. No. # sc-22591). Goat anti-
mouse immunoglobulins (DAKO A/S DK-2600 Glos-
trup, Denmark) served as the secondary antibody. Anti-
body binding was demonstrated by an amplified alkaline 
phosphatase detection system (Bio-Rad Laboratories, 
Hercules, CA, USA). 
Due to the low level of CRABP I protein detected 
with the use of a standard Western blotting method (see 
above), chemiluminescence detection was additionally 
employed to assess the expression of this protein. After 
protein isolation (described above) and protein concen-
tration measurement with the Quick Start Bradford Dye 
Reagent (Bio-Rad Laboratories) all samples were run on 
12 % SDS/polyacrylamide gel and transferred to PVDF 
membranes. Next membranes were immunoblotted with 
primary antibody against mouse CRABP I (Abcam, 
ab2816). All blots were then washed and incubated with 
an HRP-conjugated secondary antibody. The protein was 
then detected by enzyme-linked chemiluminescence with 
SuperSignal West Femto Maximum Sensitivity Substrate 
(Pierce). 
Due to the low level of RALDH2 antigen in devel-
oping heart (the protein is present only in the proepi-
cardium of 9 dpc hearts and in the epicardial layer of 
mesothelial cells of 10–13 dpc hearts) the gel for stand-
ard Western blotting method was loaded with 25 µg of 
protein instead of 10 µg.
Immunohistochemistry. Paraffin sections were seri-
ally cut and subsequently deparaffinized on a hot plate 
for 30 min, immersed for 3 × 10 min in xylene, and fi-
nally for 3 × 10 min in 96 % ethanol. After rinsing with 
PBS, the sections were treated in a microwave oven for 
2 × 5 min in 0.1 M citrate buffer (pH 6.0) in order to 
retrieve antigenic determinants. After cooling the sec-
tions were incubated with mouse monoclonal antibodies: 
anti-CRABP I (diluted 1 : 500–1 : 1000 in TBS containing 
1 % BSA) (Chemicon; cat. No. MAB5484), or with anti-
CRABP II (diluted as above 1 : 1000–1 : 1500) (Chemi-
con; cat. No. MAB5486) overnight, at +4 °C, rinsed in 
PBS, and incubated with anti-mouse IgG peroxidase 
complex (Chemicon) for 30 min. The color reaction was 
developed with 3,3΄-diaminobenzidine tetrahydrochloride 
(DAB) (Sigma-Aldrich), the reaction was stopped in dis-
tilled water and sections were counterstained with hema-
toxylin. 
For RALDH2 staining paraffin sections were depar-
affinized, treated with citrate buffer as above, and incu-
bated overnight with anti-RALDH2 antibodies (1 : 4 000). 
Subsequently sections were rinsed with PBS, incubated 
with anti-rabbit IgG-biotin (DAKO) (1:300) for 30 min, 
rinsed again with PBS, and incubated with streptavidin-
HRP complex (DAKO) (1 : 300). The color reaction was 
developed with DAB substrate.
To determine antibody specificity negative control 
stainings were performed on some sections without the 
addition of a primary antibody (Fig. S7, figures denoted 
S — see Supplementary Material at www.actabp.pl).
ReSuLTS
expression of mRNA for Crabp1, Crabp2 and Raldh2 
genes
In order to detect the expression of mRNAs for 
CRABP I and CRABP II RT-PCR technique was em-
ployed. In both control and retinoic acid-treated embry-
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os CRABP I and II mRNA was detectable from 9 dpc 
to 17 dpc (not shown). 
The embryos were exposed to RA on 8.5 dpc, as 
this is the known moment of embryonic expression of 
Crabp1 and Crabp2 (Lyn & Giguére, 1994) as well as 
based on the fact that two significant developmental 
events namely SHF addition to the heart tube and in-
teraction between CNCCs and the SHF cells occur at 
that time, which are potentially affected by RA dosage 
(Nakajima et al., 1996; 1997; Yasui et al., 1995; 1997; 
1999). Real-time PCR was employed to study quan-
titatively the expression levels of Crabp1, Crabp2 and 
Raldh2 genes. Assessment of these levels was begun 
shortly after RA treatment, at 9 dpc (hearts from ear-
lier stages were too small for tissue preparation), and 
lasted until 12 dpc when the effect of RA on the lev-
els of mRNA for all three genes seemed largely di-
minished.
We compared the basal level of expression of the ex-
amined genes at each day starting from 9 dpc. A strong 
decrease of mRNA levels for CRABP I and II was de-
tected relative to the levels at 9 dpc (Fig. 1). A decline 
in RALDH2 mRNA was observed at 10 dpc, but in the 
next days the expression increased almost to the level 
observed at 9 dpc (Fig. 1).
The effect of RA treatment, on the mRNA levels, was 
similar for all three studied genes (Crabp I, Crabp II and 
Raldh2) (Fig. 2). In samples obtained from 9 dpc RA-
treated embryos significantly lower levels of mRNAs for 
all three genes were detected compared with their con-
trol counterparts. However, in hearts from embryos col-
lected at 10 dpc a reverse pattern could be observed, as 
mRNA production seemed to be greatly enhanced by the 
earlier RA treatment. At this developmental stage such 
difference in mRNA levels was much more apparent for 
both CRABP genes than for RALDH2. Similar, although 
slightly less pronounced up-regulation of all the genes 
studied, persisted in hearts of RA-treated embryos col-
lected on the following day (11 dpc). On 12 dpc mRNA 
expression for all three genes was similar in control and 
RA-treated hearts.
Expression at the protein level
The Western blot was employed to determine wheth-
er an effect of RA on Crabp1, Crabp2 and Raldh2 genes 
similar to that found for mRNA could also be detected 
at the protein level.
The bands obtained for CRABP I and II correspond-
ed to the molecular mass of around 15–17 kDa (Fig. 3). 
Despite the low levels of CRABP I protein, which re-
mained barely detectable even when chemiluminescence 
detection was used, an increased amount of CRABP I 
protein could be observed in 9 dpc heart following RA-
treatment as compared to the control heart (Figs. 3 and 
4A). This low amount of CRABP I protein in control 
hearts did not allow a comparison of the protein lev-
els between control and RA-treated hearts at other time 
points studied. The level of CRABP II protein at 9 dpc 
in the control heart was very low and high after RA 
treatment (Fig. 4B). It remained relatively high at 10 dpc 
in both control and RA-treated hearts (as compared to 
its level in 9 dpc control heart), and declined thereafter 
(Fig. 4B). The only distinctive response to RA treatment 
was detected at 9 dpc in the levels of both CRABP I 
and II proteins suggesting similar regulation of both pro-
teins by RA. 
The expression of RALDH2 protein seemed not to 
be changed by RA treatment at 9–12 dpc (Fig. 4C) com-
pared to control hearts.
Despite the obvious initial effect of RA treatment, the 
results obtained for later days of development did not 
suggest any further major changes in the level any of 
the proteins both in the course of normal heart develop-
ment or following RA treatment. Therefore we ceased to 
study the levels of expression of all three proteins after 
12 dpc.
Figure 1. Real-time PCR for CRABP I (A), CRABP II (B) and RALDH2 (C) in control heart extracts from 9 dpc through 12 dpc
Temporal dynamics of mRNA expression was normalized to the level on 9 dpc. Each column represents the mean ± S.E.M. of four inde-
pendent experiments run in duplicate. Values marked with a star vary significantly (p < 0.05) from the level on 9 dpc.
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Localization of CRABP I, CRABP II and RALDH2 
proteins
To compare the localization of CRABP I and II pro-
teins in both control and RA-treated hearts immuno-
histochemistry was used. Although quantitative studies 
showed only a short-term response to RA treatment at 
both mRNA and protein levels, an immunohistochemical 
study was carried out until the last day of pregnancy (17 
dpc) in order to determine whether a single teratogenic 
dose of RA induces any persistent spatial changes in the 
expression of CRABP I and II within specific cardiac 
structures.
At all the stages studied (Figs. S1–S6, and not shown), 
immunolabeling for CRABP I and II was detected with-
in embryonic hearts. Both proteins were also present in 
hearts of RA-treated embryos. These results were vali-
dated with the use of negative controls (sections stained 
without the addition of a primary antibody) (Fig. S7) to 
eliminate false positives.
At the earliest stages, embryonic hearts exhibited fair-
ly homogenous staining of different areas of the myo-
cardium, which sometimes varied in intensity between 
CRABP I and II (10 dpc, Fig. S1, a and c, b and d; 
12 dpc, Fig. S3, b and f, d and h). The only notable 
exception from this homogenous staining occurred at 
Figure 2. Real-time PCR for CRABP I (A), CRABP II (B) and RALDH2 (C) in control and RA-treated heart extracts from 9 dpc through 12 
dpc
Comparison of mRNA levels for control and RA-treated hearts at each studied time point. Each column represents the mean ± S.E.M. of 
four independent experiments run in duplicate and normalized to EF2 expression. At each time point, the value in control hearts is set as 
1. For each time-point value in RA-treated hearts marked with a star varies significantly (p < 0.05) from its control counterpart.
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11 dpc in control hearts, in which CRABP II location 
exhibited a gradient of staining intensity along the myo-
cardium (Fig. S2d, e), being the strongest in the OT and 
atria. By contrast, the staining for CRABP I was evenly 
distributed within the ventricle, the atrium and the OT 
(Fig. S2a, b), and no such labeling gradient could be 
detected in RA-treated hearts stained for CRABP I or 
II (Fig. S2c, f). Besides this distinctive staining pattern 
in the myocardium, it is also worth noting that at 12 
dpc after RA treatment the staining for anti-CRABP I 
exhibited a patchy pattern in aggregations of cells dis-
tributed evenly within the compact layer of the ventri-
cles, ventricular trabeculae, the atrial myocardium, and 
the scattered cells of the endocardial cushions (Fig. S3c 
and d). Higher magnification photographs revealed that 
this labeling was mostly located in the cytoplasm of the 
cells (Fig. S3, inset in d). Such labeling pattern resem-
bling patches or dots could also be detected on some of 
the following days of development both in control (not 
shown) and RA-treated (Fig. S4c, d) hearts.
Additionally, a strong staining of endocardial endothe-
lial cells (EECs) for CRABP II could be observed within 
the ventricles (Fig. S3b, f) and the atria (not shown) at 
12 dpc as well as in EECs of the OT cushions, and the 
developing semilunar valves, great arteries (Fig. S4e, f, g, 
Fig. S5f, g) and atria (Fig. S5h) at 13–14 dpc. Moreover, 
the mesenchymal cap of the forming interatrial septum 
exhibited staining for CRABP II at 11 (not shown) and 
12 dpc (Fig. S3e, white arrow).
On the following days of heart development (13, 14 
dpc) homogenous labeling for CRABP I and II was de-
tected in the ventricles, atria and 
the great arteries of control hearts 
(Fig. S4a, b, e, f) and hearts from 
RA-treated embryos (Fig. S4c, d, g, 
h; Fig. S5a, b, e, f) except for 14 
dpc when the walls of great arter-
ies exhibited significantly dimin-
ished staining (Fig. S5a, b, e, f, g). 
Additionally, at 13 dpc and 14 dpc 
in both control and RA-treated 
hearts, some of the mesenchymal 
cells of the OT cushions (Fig. S4a, 
b, e, f) and the forming aorto-
pulmonary septum (Fig. S5c, e, f, 
g) were labeled for CRABP I and 
II. The number of CRABP I and 
II positive cells in the OT cushion 
was, however, diminished in RA-
treated hearts. As shown in insets 
in Fig. S4f and Fig. S5g the color 
reaction in these cells was mainly 
restricted to the cytoplasmic com-
partment. 
At later stages of development 
(15–17 dpc) in control hearts as 
well as those from RA-treated 
embryos the staining for CRABP 
I and II was evenly distributed 
within the myocardium except for 
the wall of the great vessels and 
the semilunar valves which showed 
no staining for either protein (not 
shown). At these stages of devel-
opment staining for CRABP I and 
II was detected in the mesenchy-
mal cells of the aorto-pulmonary 
septum (not shown) in hearts from 
control and RA-treated embryos. Labeling for both pro-
teins was also present in the mesenchyme of the atriov-
entricular valves, localized close to the surface adjacent 
to the ventricular lumen in the control hearts. Similar 
staining for CRABP I and II could be observed in the 
mesenchyme of the atrioventricular valves following RA 
administration.
Throughout the stages studied the epicardium re-
mained weakly stained for both CRABP I and II in con-
trol and RA-treated hearts. Interestingly in 13-dpc hearts 
the mesenchymal tissue underneath the epicardial layer 
exhibited positive staining for CRABP I in RA-treated 
hearts (Fig. S4d). 
Besides the heart, color reaction was also observed in 
other developing tissues of the studied embryos, most 
notably in the neural epithelium and neural ganglia, gut 
mesenchyme, somites, limb mesenchyme, mesonephros, 
gonads and tail mesenchyme, which is in accordance 
with previous studies (Perez-Castro et al., 1989; Maden et 
al., 1991; Ruberte et al., 1991; 1992; Kleinjan et al., 1997). 
Staining for CRABP II was absent from the develop-
ing hepatic, osseous and cartilaginous tissue at all time 
points of the study.
Additionally, immunohistochemical staining for reti-
naldehyde dehydrogenase II (RALDH2) was performed 
in 10–12 dpc hearts. This technique was employed to 
determine areas of endogenous RA synthesis within 
the control and RA-treated hearts at these early stages 
of development, corresponding to the stages when RA-
mediated change of mRNA and protein levels for Crabp1 
and Crabp2 genes was detected. RALDH2 was detected 
Figure 3. Western blot analysis of CRABP I (A), CRABP II (B) and RALDH2 (C) expression 
between 9 and 12 dpc in control and RA-treated heart extracts.
The bands detected with anti-CRABP I (Abcam, ab2816) and anti-CRABP II (Chemicon, 
MAB5486) antibodies correspond to molecular mass of about 15–17 kDa, confirming an-
tibody specificity. The band of 55 kDa corresponds to RALDH2 protein (C). For CRABP I de-
tection control tissue (brain) was loaded in the first lane. For RALDH2 detection control tis-
sue consisted of mouse testis homogenate loaded in the first lane at 25 μg (T1) and in the 
second lane at 50 μg (T2).
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in the forming epicardium of 10, 11 and 12-dpc hearts 
(Fig. S6a–f). Additionally, this enzyme was present in 
some subepicardial cells penetrating towards the myo-
cardium of 12-dpc hearts (not shown). These scattered 
cells are probably derived from the epicardial layer. In 
the RA-treated hearts from 10 and 11 dpc embryos, 
RALDH2 staining of the epicardial tissue was markedly 
reduced (Fig. S6d, e) and at 10 dpc it was also present 
in the myocardium, most notably in the region of the 
OT (Fig. S6d). Exceptionally strong RALDH2 staining 
was also observed in the surrounding extracardiac tissues 
(Fig. S6d, white arrow). Additionally, RALDH2 labeling 
was detected in proepicardial vesicles of control (Fig. S6, 
b) and RA-treated (inset in Fig. S6e) 9, 10 and 11-dpc 
hearts and in the forming blood islands of RA-treated, 
12-dpc heart (Fig. S6f).
DISCuSSION
Although embryonic expression of CRABP I and II in 
the mouse has been described by several research groups 
(Ruberte et al., 1991; 1992; Lyn & Giguére, 1994; Leon-
ard et al., 1995), the presence of these proteins in the de-
veloping heart has not been given much attention. The 
results of studies aimed to detect embryonic expression 
of CRABP proteins seem to be somewhat contradictory 
in relation to this organ. While 
some authors describe cardiac 
expression of these proteins, al-
beit at low levels as compared 
to other embryonic structures 
(Perez-Castro et al., 1989; Ru-
berthe et al., 1991; 1992), others 
failed to detect expression of 
these proteins in this develop-
ing organ (Kleinjan et al., 1997). 
Maden (1994) demonstrated 
CRABP II in the heart where-
as CRABP I was not detected. 
These inconsistencies may be 
due to sensitivity of particular 
methods used in those studies. 
Therefore in the present 
study we focused specifically on 
embryonic mouse heart, aim-
ing to describe the dynamics 
of CRABPs expression in this 
organ at a critical period of its 
development. We also want-
ed to study the expression of 
RALDH2, the major RA-syn-
thesizing enzyme in the heart, 
and the influence of exogenous 
RA treatment on RALDH2 
protein and mRNA expression.
In this study we have shown 
that CRABP I and II proteins 
and their genes are expressed 
in embryonic mouse hearts at 
9–17 dpc. We have demonstrat-
ed that: 
1. The level of mRNA for 
CRABP I and II varies among 
the developmental stages of 
normal hearts and hearts from 
embryos treated with a single 
exogenous dose of RA. 
2. As compared to control 
samples, the level of mRNA for both CRABP I and II 
after RA treatment decreased at 9 dpc, and increased at 
10 dpc. The same tendency was observed for mRNA of 
RALDH2.
3. RA treatment increased the expression of CRABP 
I and II protein in the heart within the first 24 h fol-
lowing treatment, with a subsequent decrease to a level 
found in control embryos. RA did not cause any varia-
tion in RALDH2 protein level within the first 24 h after 
treatment.
4. A staining “gradient” of CRABP II was observed 
in the arterial and venous poles of 11-dpc hearts, which 
may reflect the fact that RA mediates a developmental 
signal for these areas at that time. It is also possible that 
it is connected with the invasion of these structures by 
CNCCs. Both CRABP proteins were expressed in some 
cells within the OT. At the cellular level CRABP II was 
found transiently in some cells which remained negative 
for CRABP I throughout the study, for instance the en-
docardial endothelial cells. 
The variation of mRNA levels for CRABP I and II 
within the 48 h after RA treatment as compared to con-
trol hearts suggests that this single dose of RA exerts its 
effect on the expression of both genes. A similar ten-
dency was observed for the Raldh2 gene. The increased 
level of CRABP I and II protein in embryonic hearts 
Figure 4. Optical density of Western blot for CRABP I (A), CRAPB II (B) and RALDH2 (C) pro-
tein bands
Ponceau S optical density was used as a correction factor for quantification.
26           2011E. Stachurska and others
within the first 24 h after RA treatment suggests that at 
the protein level CRABP I and II are also subject to RA 
regulation. This effect may be caused by an immediate 
up-regulation of mRNA for CRABP I and II, within a 
few hours after RA treatment, which would be consist-
ent with previous observations on up-regulation of their 
genes in various cellular models in vitro (Boylan & Gu-
das, 1992; Lyn & Giguére, 1994; Williams et al., 2004). 
After studying the effect of RA treatment on the expres-
sion of various neural crest genes, Williams et al. (2004) 
classified Crabp II into a group of genes characterized 
by an immediate alteration of their mRNA levels in 
response to RA. Such reaction to RA occurred mostly 
within 6 h after treatment, and ceased after 12–24 h. In 
our study both CRABP I and II mRNAs were down-
regulated after 12 h following RA administration, that is 
at 9 dpc. In relation to these results, the increased pro-
tein level in 9-dpc RA-treated hearts observed in our 
study could be due to immediate gene upregulation by 
RA. In this scenario, an increased level of CRABP I and 
II protein could be observed even at 9 dpc, that is 12 h 
after RA dosage, when mRNA for these genes, initially 
up-regulated directly after RA dosage, had already been 
degraded. In addition a down-regulation of mRNA for 
CRABP I and II could be a result of negative feedback 
regulation of these genes by their products, that is by an 
excess of CRABP I and II proteins. At this time point 
(9 dpc) CNCCs, which are considered to be the major 
source of CRABP proteins in the developing organs, are 
not yet present in the heart (Hildreth et al., 2008), there-
fore the abundance of CRABP I and II proteins follow-
ing RA treatment is likely the result of RA-induced ec-
topic expression. Subsequent upregulation of mRNA for 
CRABP I and II proteins at 10 dpc may indicate that a 
single dose of RA given at 8.5 dpc may also exert a fur-
ther, delayed effect on their expression. We presume that 
this secondary upregulation may become more complex, 
not solely dependent on RA action, but involving other 
regulatory factors, for instance a diminished amount of 
gene end-products.
It is worth noting that specific molecular factors in-
volved in RA-driven regulation of Crabp1 and Crabp2 
genes are not yet fully determined. A study by Wang et 
al. (2004) points to a likely role of BAF180 of a chroma-
tin remodeling complex PBAF in coactivation of Crabp2 
gene presumably as a cofactor of nuclear RA receptors 
such as RXRa. Ablation of BAF180 causes cardiac de-
fects characteristic for disrupted RA signaling pathway 
(Kastner et al., 1994; Sucov et al., 1994) such as hypo-
plastic ventricular myocardium and VSD (Wang et al., 
2004). BAF180 has also been characterized as a factor 
indispensable for Crabp2 response to RA and this pro-
tein has been evidenced to bind directly to Crabp2 pro-
moter region (Wang et al., 2004). An effect of BAF180 
ablation on the level of Crabp2 gene expression has 
also been described. It seems that BAF180 ablation and 
thus disruption of RA signaling pathway may cause ei-
ther an increase or down-regulation (Wang et al., 2004) 
of expression of this gene. Such discrepancies may be 
explained by the different effect of RA signaling on par-
ticular genes based on specific localization in the embry-
onic heart, as the effect of RA is thought to be highly 
cell- and tissue-specific, and may be different for the 
same gene depending on the site of its expression (Wang 
et al., 2004, and references therein). 
The fluctuations in the levels of mRNA and protein 
for CRABP I and II are the highest during the first 
72 h following RA treatment. It is known that at this 
stage of cardiac development, CNCCs reach the heart 
(Poelmann & Gittenberger-de Groot, 1999; Jiang et 
al., 2000; Hildreth et al., 2008) and the OT undergoes 
marked differentiation during which SHF cells are 
added to the developing OT and the proper alignment 
of the great arteries with their respective ventricles oc-
curs (Kelly et al., 2001; Mjaatvedt et al., 2001; Yelbuz et 
al., 2002; Waldo et al., 2005; Buckingham et al., 2005; 
Rochais et al., 2009). At this time a “staining gradient” 
with anti-CRABP II was observed. This staining gradi-
ent for CRABP II, a marker of NCCs, was detected in 
the OT and the venous pole of 11-dpc control hearts. 
Firstly, such localization of staining may mark the car-
diac areas populated by the NCCs, as both CRABP I 
and II are known to be molecular markers of these 
cells (Williams et al., 2004; Ilagan et al., 2006). This gra-
dient, however, was not observed with anti-CRABP I 
antibodies, which may indicate that these two proteins 
are controlled differently. Additionally, this staining 
pattern may also indicate the sites of developmental 
action of RA signaling since CRABP II is though to 
transduce the RA signal (McCaffery & Dräger, 2000; 
Ross et al., 2000; Zhelyaznik et al., 2003). These areas 
seem to converge with the fields of RA action within 
the heart which have been characterized by Moss et al. 
(1998), where both synthesis (sinus venosus, atria) and 
response to RA (sinus venosus, atria, and conotruncal 
area) is known to occur. SHF cells are themselves ex-
tremely sensitive to RA action during normal heart de-
velopment, which has been demonstrated in mammals 
and other vertebrates (Collop et al., 2006; Vermot et al., 
2006; Ryckebusch et al., 2008, Sirbu et al., 2008; Wax-
man et al., 2008; Rochais et al., 2009). Thus an excess 
of RA in our model causes heart malformations in the 
area where derivatives of the SHF are located and NCC 
cells accumulate (OT). Excessive RA signaling is known 
to disturb correct migration of the NCCs (Moss et al., 
1998; Niederreither et al., 1999) and perturbs signaling 
between NCCs and SHF cells via action on Fgf8 (Hut-
son et al., 2006; Ilagan et al., 2006; Park et al., 2006). 
Fgf2 and Fgf9 are two other retinoid-induced growth 
factors which regulate heart development (Lin et al., 
2010). It is interesting whether CRABP II participates 
in RA-dependent control of SHF and NCC cellular 
populations contributing to the arterial and the venous 
pole of the heart at that time. In that case CRABP II 
could be involved in sustaining locally-specific levels of 
RA signaling in these areas, which could be different 
from the levels of this signal in the ventricular com-
partment of the heart tube, based on the distinct origin 
of SHF and the NCCs. Exogenous, teratogenic doses 
of RA could affect this highly specific signaling and the 
expression of CRABP II as its component suppressing 
its gradient as seen at 11 dpc. Ectopic expression of 
RALDH2 in the outflow portion of the heart at 10 dpc 
could also point to a role of excess RA in disrupting 
the normal pattern of endogenous RA signaling. 
However, the putative participation of CRABP II in 
mediating RA signal for the developing heart requires 
confirmation with more detailed studies. The question 
whether suppresion of CRABP II staining gradient fol-
lowing RA treatment represents diminished contribu-
tion of the NCCs to the venous and arterial pole of the 
heart also remains open, as more molecular markers of 
the NCCs, preferably those not regulated by RA, would 
have to be used in order to resolve it. 
At the intracellular level both proteins (CRABP I and 
II) were mostly located in the cytoplasmic compartments 
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of cardiac myocytes and other cell types at these stages 
of development. 
Interestingly, groups of cells in the OT cushions and 
the atrioventricular cushions at 11–13 dpc expressed 
both proteins and the number of these cells diminished 
after RA treatment. Also the labeling intensity between 
CRABP I and CRABP II in these groups of cells varied. 
This would be consistent with previous studies describ-
ing embryonic contribution of NCCs to specific car-
diac structures (Hildreth et al., 2008), as well as reports 
claiming that such contribution can be diminished by 
RA treatment (Maden et al., 1996; Hoover et al., 2008). 
However, as stated above it is not clear whether such di-
minished staining can be directly identified with a lower 
contribution of the NCCs.
At 13–14 dpc a strong, distinct staining for CRABP 
II was also detected in the endocardial endothelial cells 
(EECs) of the OT, in the EECs of the right ventricular 
infundibulum, atria, and the forming semilunar valves in 
both control and RA-treated hearts. In contrast, CRABP 
I was absent from the EECs, suggesting that the roles 
played by both proteins in RA metabolism in various 
structures of the developing heart are different. Such a 
strong labeling for CRABP II might be explained by its 
upregulation by endogenous RA, as, according to the lit-
erature, the RA signal for cardiomyocyte development 
may come from the epicardium as well as from the en-
docardium (Kang & Sucov, 2005). The developmental 
signal for nonmyogenic structures of the heart, such as 
the aorta and pulmonary arteries, semilunar valves and 
atrioventricular valves, which have been classified into 
one of cardiac “fields” of RA morphogenetic action 
(Moss et al., 1998), may be derived from the endocar-
dium, initiated by an RA-synthesizing enzyme other than 
RALDH2 (as suggested in: Moss et al., 1998) and medi-
ated specifically by CRABP II. On the other hand, RA 
signaling for the atrial and ventricular myocardium seems 
to be generated in the epicardium by RALDH2 and fur-
ther mediated by CRABP proteins present in the ven-
tricular and atrial myocytes. The presence of RALDH2 
enzyme detected within the epicardium in this study as 
well as in previous publications (Moss et al., 1998; Berg-
gren et al., 1999; Xavier-Neto et al., 2000; Berggren et al., 
2001; Hoover et al., 2008) combined with the presence 
of cells stained positively for RALDH2, which migrate 
from the epicardium towards myocardium, could also 
support these claims.
RALDH2 has been characterized as the major RA 
synthesizing enzyme in the embryo (Zhao et al., 1996; 
Berggren et al., 1999; Vermot et al., 2006). We were in-
terested whether exogenous RA would alter the level of 
Raldh2 gene expression. We observed a down-regulation 
of Raldh2 mRNA in RA-treated hearts at 9 dpc, but at 
10 and 11 dpc this gene was up-regulated. Susceptibil-
ity of this enzyme to regulation by its own product has 
been proven in P19 embryonal carcinoma cells (Zhao 
et al., 1996). Similarly Napoli (1999) classifies Raldh2 as 
an RA-responsive gene, noticing that its response to RA 
might be tissue specific. A response of RALDH2 to RA 
has also been detected in some structures of the murine 
embryo, 12 and 27 h after maternal RA treatment, which 
was administered precisely at 8.5 dpc (Neiderreither et 
al., 1997b). Regardless of the exact mechanisms respon-
sible for the fact that the reaction of RALDH2 to exog-
enous RA varied in time, these results clearly show that 
a single dose of retinoic acid administered at the critical 
time of cardiogenesis (8.5 dpc) may affect production of 
endogenous RA within the developing heart. 
Furthermore, immunohistochemical staining with anti-
RALDH2 antibodies following RA treatment reveals ad-
ditional signal, although weak, in the myocardium of the 
OT and the ventricles at 10 dpc. This extopic expression 
of RALDH2 does not, however, correlate with the level 
of total RALDH2 protein expression at that time (Fig. 
4C). 
A strong distinctive pattern of RALDH2 labeling is 
also present in the distal portion of the outflow tract as 
well as in surrounding tissues. These areas are known to 
be in spatial contact with the NCCs immediately before 
the immigration of these cells into the outflow tract. It 
is thought that RALDH2 is not expressed in the migrat-
ing CNCCs (Niederreither et al., 1997a; Berggren et al., 
1999). However, it is believed that for successful mi-
gration of these cells, a specific pattern of RA must be 
provided throughout their migratory pathways (Nieder-
reither et al., 1997a; Berggren et al., 1999). It is therefore 
possible that aberrant induction of RALDH2 expression 
in the OT of 10-dpc hearts could lead to reduced migra-
tion of NCCs into this structure, and in consequence to 
the OT septation defects persistent in this model (Yas-
ui et al., 1995; 1997; 1999; Nakajima et al., 1996; 1997). 
As stated above, the gradient of CRABP II affected by 
RA at 11 dpc seems to be consistent with this hypoth-
esis. However, further studies are required to determine 
whether in this case the abolished gradient of CRABP 
II reflects specifically the reduction in the number of 
migrating NCCs. Alternatively, both changes in spatial 
expression of CRABP II and RALDH2 may reflect the 
increased sensitivity of the affected heart areas to excess 
RA signaling.
Regardless of the specific mechanism it is evident that 
expression of both Crabp I and II as well as Raldh2 genes 
(mRNA levels) is responsive to RA excess administered 
during the heart looping stage.
Based on our findings we cannot deduce what are 
the exact regulatory mechanisms of CRABPs΄ action in 
the RA signaling network, however, RA-induced regula-
tion of mRNA and protein levels of both CRABPs at 
the stages of cardiac loop formation SHF cells addition 
to the outflow tract and subsequent OT alignment, sug-
gests that these proteins may be involved in these major 
developing processes of the heart and may mediate RA 
signaling.
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